Review



finnish national guideline for chronic obstructive pulmonary disease (copd)  (Duodecim Medical Publications)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Duodecim Medical Publications finnish national guideline for chronic obstructive pulmonary disease (copd)
    Classification of the severity of obstruction and the clinical severity of chronic <t> obstructive pulmonary disease </t> (COPD)
    Finnish National Guideline For Chronic Obstructive Pulmonary Disease (Copd), supplied by Duodecim Medical Publications, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/finnish+national+guideline+for+chronic+obstructive+pulmonary+disease+(copd)/finnish+national+guideline+for+chronic+obstructive+pulmonary+disease++copd+/pmc04409821-35-17-4
    Average 90 stars, based on 1 article reviews
    finnish national guideline for chronic obstructive pulmonary disease (copd) - by Bioz Stars, 2026-11
    90/100 stars

    Images

    1) Product Images from "Diagnosis and Pharmacotherapy of Stable Chronic Obstructive Pulmonary Disease: The Finnish Guidelines"

    Article Title: Diagnosis and Pharmacotherapy of Stable Chronic Obstructive Pulmonary Disease: The Finnish Guidelines

    Journal: Basic & Clinical Pharmacology & Toxicology

    doi: 10.1111/bcpt.12366

    Classification of the severity of obstruction and the clinical severity of chronic  obstructive pulmonary disease  (COPD)
    Figure Legend Snippet: Classification of the severity of obstruction and the clinical severity of chronic obstructive pulmonary disease (COPD)

    Techniques Used:

    Aims of the pharmacotherapy of chronic obstructive pulmonary disease (COPD) and principles for the evaluation whether to continue or discontinue the current medication.
    Figure Legend Snippet: Aims of the pharmacotherapy of chronic obstructive pulmonary disease (COPD) and principles for the evaluation whether to continue or discontinue the current medication.

    Techniques Used:

    Pharmacological compounds used in the therapy of chronic  obstructive pulmonary disease
    Figure Legend Snippet: Pharmacological compounds used in the therapy of chronic obstructive pulmonary disease

    Techniques Used:

    Effects of smoking cessation, exercise and various pharmacotherapies in the treatment of chronic  obstructive pulmonary disease  (COPD)
    Figure Legend Snippet: Effects of smoking cessation, exercise and various pharmacotherapies in the treatment of chronic obstructive pulmonary disease (COPD)

    Techniques Used: Biomarker Discovery

    The principles of diagnostics and phenotype-specific therapy of chronic obstructive pulmonary disease (COPD). Of note, the current indication for the use of different fixed combinations of inhaled glucocorticoid ICS and long-acting β 2 -agonist (LABA) in COPD is frequent exacerbations despite the use of appropriate bronchodilator therapy, but the FEV 1 ranges from <50% predicted (budesonide–formoterol, beclomethasone dipropionate–formoterol) to <60% predicted (fluticasone propionate–salmeterol) and to <70% predicted (fluticasone furoate–vilanterol).
    Figure Legend Snippet: The principles of diagnostics and phenotype-specific therapy of chronic obstructive pulmonary disease (COPD). Of note, the current indication for the use of different fixed combinations of inhaled glucocorticoid ICS and long-acting β 2 -agonist (LABA) in COPD is frequent exacerbations despite the use of appropriate bronchodilator therapy, but the FEV 1 ranges from <50% predicted (budesonide–formoterol, beclomethasone dipropionate–formoterol) to <60% predicted (fluticasone propionate–salmeterol) and to <70% predicted (fluticasone furoate–vilanterol).

    Techniques Used:

    The principles of combining drugs used to treat chronic  obstructive pulmonary disease  (COPD). The general rule of drug therapy of COPD is that two drugs belonging to the same group or having similar mechanism of action should not be combined. The exception to this rule is the simultaneous use of short- and long-acting β 2 -agonists that is allowed and often is meaningful
    Figure Legend Snippet: The principles of combining drugs used to treat chronic obstructive pulmonary disease (COPD). The general rule of drug therapy of COPD is that two drugs belonging to the same group or having similar mechanism of action should not be combined. The exception to this rule is the simultaneous use of short- and long-acting β 2 -agonists that is allowed and often is meaningful

    Techniques Used: Medications



    Similar Products

    90
    Duodecim Medical Publications finnish national guideline for chronic obstructive pulmonary disease (copd)
    Classification of the severity of obstruction and the clinical severity of chronic <t> obstructive pulmonary disease </t> (COPD)
    Finnish National Guideline For Chronic Obstructive Pulmonary Disease (Copd), supplied by Duodecim Medical Publications, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/finnish+national+guideline+for+chronic+obstructive+pulmonary+disease+(copd)/finnish+national+guideline+for+chronic+obstructive+pulmonary+disease++copd+/pmc04409821-35-17-4
    Average 90 stars, based on 1 article reviews
    finnish national guideline for chronic obstructive pulmonary disease (copd) - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    Image Search Results


    Classification of the severity of obstruction and the clinical severity of chronic  obstructive pulmonary disease  (COPD)

    Journal: Basic & Clinical Pharmacology & Toxicology

    Article Title: Diagnosis and Pharmacotherapy of Stable Chronic Obstructive Pulmonary Disease: The Finnish Guidelines

    doi: 10.1111/bcpt.12366

    Figure Lengend Snippet: Classification of the severity of obstruction and the clinical severity of chronic obstructive pulmonary disease (COPD)

    Article Snippet: The Finnish Medical Society Duodecim initiated and managed the update of the Finnish national guideline for chronic obstructive pulmonary disease (COPD).

    Techniques:

    Aims of the pharmacotherapy of chronic obstructive pulmonary disease (COPD) and principles for the evaluation whether to continue or discontinue the current medication.

    Journal: Basic & Clinical Pharmacology & Toxicology

    Article Title: Diagnosis and Pharmacotherapy of Stable Chronic Obstructive Pulmonary Disease: The Finnish Guidelines

    doi: 10.1111/bcpt.12366

    Figure Lengend Snippet: Aims of the pharmacotherapy of chronic obstructive pulmonary disease (COPD) and principles for the evaluation whether to continue or discontinue the current medication.

    Article Snippet: The Finnish Medical Society Duodecim initiated and managed the update of the Finnish national guideline for chronic obstructive pulmonary disease (COPD).

    Techniques:

    Pharmacological compounds used in the therapy of chronic  obstructive pulmonary disease

    Journal: Basic & Clinical Pharmacology & Toxicology

    Article Title: Diagnosis and Pharmacotherapy of Stable Chronic Obstructive Pulmonary Disease: The Finnish Guidelines

    doi: 10.1111/bcpt.12366

    Figure Lengend Snippet: Pharmacological compounds used in the therapy of chronic obstructive pulmonary disease

    Article Snippet: The Finnish Medical Society Duodecim initiated and managed the update of the Finnish national guideline for chronic obstructive pulmonary disease (COPD).

    Techniques:

    Effects of smoking cessation, exercise and various pharmacotherapies in the treatment of chronic  obstructive pulmonary disease  (COPD)

    Journal: Basic & Clinical Pharmacology & Toxicology

    Article Title: Diagnosis and Pharmacotherapy of Stable Chronic Obstructive Pulmonary Disease: The Finnish Guidelines

    doi: 10.1111/bcpt.12366

    Figure Lengend Snippet: Effects of smoking cessation, exercise and various pharmacotherapies in the treatment of chronic obstructive pulmonary disease (COPD)

    Article Snippet: The Finnish Medical Society Duodecim initiated and managed the update of the Finnish national guideline for chronic obstructive pulmonary disease (COPD).

    Techniques: Biomarker Discovery

    The principles of diagnostics and phenotype-specific therapy of chronic obstructive pulmonary disease (COPD). Of note, the current indication for the use of different fixed combinations of inhaled glucocorticoid ICS and long-acting β 2 -agonist (LABA) in COPD is frequent exacerbations despite the use of appropriate bronchodilator therapy, but the FEV 1 ranges from <50% predicted (budesonide–formoterol, beclomethasone dipropionate–formoterol) to <60% predicted (fluticasone propionate–salmeterol) and to <70% predicted (fluticasone furoate–vilanterol).

    Journal: Basic & Clinical Pharmacology & Toxicology

    Article Title: Diagnosis and Pharmacotherapy of Stable Chronic Obstructive Pulmonary Disease: The Finnish Guidelines

    doi: 10.1111/bcpt.12366

    Figure Lengend Snippet: The principles of diagnostics and phenotype-specific therapy of chronic obstructive pulmonary disease (COPD). Of note, the current indication for the use of different fixed combinations of inhaled glucocorticoid ICS and long-acting β 2 -agonist (LABA) in COPD is frequent exacerbations despite the use of appropriate bronchodilator therapy, but the FEV 1 ranges from <50% predicted (budesonide–formoterol, beclomethasone dipropionate–formoterol) to <60% predicted (fluticasone propionate–salmeterol) and to <70% predicted (fluticasone furoate–vilanterol).

    Article Snippet: The Finnish Medical Society Duodecim initiated and managed the update of the Finnish national guideline for chronic obstructive pulmonary disease (COPD).

    Techniques:

    The principles of combining drugs used to treat chronic  obstructive pulmonary disease  (COPD). The general rule of drug therapy of COPD is that two drugs belonging to the same group or having similar mechanism of action should not be combined. The exception to this rule is the simultaneous use of short- and long-acting β 2 -agonists that is allowed and often is meaningful

    Journal: Basic & Clinical Pharmacology & Toxicology

    Article Title: Diagnosis and Pharmacotherapy of Stable Chronic Obstructive Pulmonary Disease: The Finnish Guidelines

    doi: 10.1111/bcpt.12366

    Figure Lengend Snippet: The principles of combining drugs used to treat chronic obstructive pulmonary disease (COPD). The general rule of drug therapy of COPD is that two drugs belonging to the same group or having similar mechanism of action should not be combined. The exception to this rule is the simultaneous use of short- and long-acting β 2 -agonists that is allowed and often is meaningful

    Article Snippet: The Finnish Medical Society Duodecim initiated and managed the update of the Finnish national guideline for chronic obstructive pulmonary disease (COPD).

    Techniques: Medications